Author:
Koren Michael J.,Sabatine Marc S.,Giugliano Robert P.,Langslet Gisle,Wiviott Stephen D.,Ruzza Andrea,Ma Yuhui,Hamer Andrew W.,Wasserman Scott M.,Raal Frederick J.
Subject
Cardiology and Cardiovascular Medicine
Reference23 articles.
1. PCSK9 inhibitors: mechanism of action, efficacy, and safety;Roth;Rev Cardiovasc Med,2018
2. Repatha (evolocumab): second PCSK9 inhibitor approved by the FDA for patients with familial hypercholesterolemia;Fala;Am Health Drug Benefits,2016
3. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials;Stein;Eur Heart J,2014
4. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial;Raal;Lancet,2015
5. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial;Raal;Lancet,2015
Cited by
111 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献